Search company, investor...

Predict your next investment

Corporate Venture
HEALTHCARE | Pharmaceuticals / Drugs
sanofigenzymebioventures.com

Investments

25

Portfolio Exits

13

About Sanofi-Genzyme BioVentures

Sanofi-Genzyme Ventures is a corporate venture capital fund dedicated to helping Genzyme Corporation achieve its strategic goals. Founded in 2001, the $100 million fund has a current portfolio of direct corporate investments and has taken LP positions in funds managed by life-science focused VC firms. Through its direct investments in private early-stage companies, the fund aims to forge relationships which may lead to larger collaborations in the future. Genzyme Ventures is able to leverage the entire Genzyme organization, including its global experience and expertise in R&D, reimbursement, and commercialization, to provide portfolio companies with invaluable advice and assistance. Its Limited Partnership investments provide insight into the broader healthcare innovation landscape

Headquarters Location

500 Kendall Street

Cambridge, Massachusetts, 02142,

United States

Want to inform investors similar to Sanofi-Genzyme BioVentures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Sanofi-Genzyme BioVentures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sanofi-Genzyme BioVentures in 3 CB Insights research briefs, most recently on Nov 30, 2022.

Latest Sanofi-Genzyme BioVentures News

Sanofi pumps $750M into VC unit to push deeper into biotech investing | Fierce Biotech

Jan 17, 2023

Sanofi has thrown its financial weight behind its venture capital unit, making a $750 million, multi-year commitment to enable the financier to build on a year in which it backed 10 companies globally. Sanofi Ventures is a well-established player in the biotech VC space, with its roots dating back to the formation of Sanofi-Genzyme BioVentures in 2011 and beyond that to the establishment of Genzyme Ventures a decade earlier. But Sanofi has largely stayed in the shadows, leaving its venture unit to build out a portfolio without publicly disclosing the details of how it supports the fund.

Sanofi-Genzyme BioVentures Investments

25 Investments

Sanofi-Genzyme BioVentures has made 25 investments. Their latest investment was in Omada Health as part of their Series C - II on June 6, 2017.

CBI Logo

Sanofi-Genzyme BioVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/14/2017

Series C - II

Omada Health

$50M

Yes

2

4/26/2017

Series B - II

Evidation

$10M

Yes

2

4/25/2017

Series C

Science 37

$29M

No

2

10/18/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/10/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2017

4/26/2017

4/25/2017

10/18/2016

2/10/2016

Round

Series C - II

Series B - II

Series C

Series B

Series A

Company

Omada Health

Evidation

Science 37

Subscribe to see more

Subscribe to see more

Amount

$50M

$10M

$29M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Sanofi-Genzyme BioVentures Portfolio Exits

13 Portfolio Exits

Sanofi-Genzyme BioVentures has 13 portfolio exits. Their latest portfolio exit was Science 37 on May 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/7/2021

Acq - Pending

$99M

7

8/24/2020

Reverse Merger

$99M

8

3/29/2018

IPO

$99M

Public

3

5/5/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/22/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/7/2021

8/24/2020

3/29/2018

5/5/2017

6/22/2016

Exit

Acq - Pending

Reverse Merger

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

7

8

3

10

10

Sanofi-Genzyme BioVentures Acquisitions

3 Acquisitions

Sanofi-Genzyme BioVentures acquired 3 companies. Their latest acquisition was AnorMed on November 07, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/7/2006

$99M

Acquired

1

2/8/2005

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/31/1996

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

11/7/2006

2/8/2005

5/31/1996

Investment Stage

Series D

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Sanofi-Genzyme BioVentures Team

5 Team Members

Sanofi-Genzyme BioVentures has 5 team members, including current Senior Vice President, James P Sherblom.

Name

Work History

Title

Status

James P Sherblom

Senior Vice President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

James P Sherblom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Senior Vice President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.